March 10, 2021
- 70% of people surveyed have experienced one or more new sleep
challenges since the start of the pandemic
- 72% of surveyed sleep apnea patients who discontinued CPAP
therapy cited COVID-19 related reasons
- 58% reported a willingness to use telehealth for a sleep
related concern, aligning with Philips’ commitment to delivering
connected care telehealth support to people at home
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced
the findings of its 6th annual sleep survey in a report titled
Seeking Solutions: How COVID-19 Changed Sleep Around the World.
Almost a year since the onset of the COVID-19 pandemic, Philips
surveyed 13,000 adults in 13 countries to capture attitudes,
perceptions, and behaviors around sleep. This year’s survey reveals
that, since the beginning of COVID-19, 70% of respondents
experienced one or more new sleep challenges, with 60% reporting
that the pandemic had directly impacted their ability to sleep
well. It also reveals that while such challenges have been
widespread, sleep apnea patients have been disproportionately
affected. The good news is there is strong interest in implementing
tools and strategies – such as telehealth, online information
resources, and lifestyle changes – to address these challenges.
More people are turning to online resources and telehealth
for sleep concerns While some people may have relied on
lifestyle strategies – such as soothing music, meditation or
reading – to address their sleep woes, many turned to online
searches to learn more about treatments to improve sleep (34%).
With the increased reliance on telehealth during the pandemic, more
than half (58%) of respondents expressed a willingness to seek help
for sleep related concerns in future from a sleep specialist via
telehealth services, although many have yet to take that step. The
majority (70%) currently believed it would be difficult [1] to find
a sleep specialist through an online or telephone-based
program.
“This year’s survey results confirm what we’ve known to be true
for a while: with the right solutions, care doesn’t have to be
defined by a place, but instead by the needs of the individual and
his or her condition,” said Dr. Teofilo Lee-Chiong, MD, Chief
Medical Liaison, Sleep & Respiratory Care at Philips. “The
tools required to deliver telehealth efficiently and reliably
already exist, and the interest from consumers is apparent,
particularly in the face of COVID-19. When used properly, sleep
telehealth has the potential to enhance efficiency and quality of
care, improve health outcomes, empower patients to make informed
decisions, and provide equitable healthcare for all. Extending the
reach of patient care through technology means we empower providers
to confidently guide patients across multiple settings and
transitions of care, driving better health outcomes.”
In 2020, Philips furthered the care-from-anywhere approach in
the sleep sector by introducing a clinically-validated, low-touch
CPAP Mask Selector tool that can be used remotely from the comfort
of the patient’s home. As part of Philips’ complete home-based
end-to-end solution that includes Alice NightOne home sleep test,
Home Delivery and Remote Set-up kit, and therapy adherence virtual
services, Philips’ 2D Mask Selector option means patients with
sleep issues may not even need to leave home to receive the
diagnosis and treatment they need. On the provider side, clinicians
can remotely manage their sleep and respiratory patients using
Philips Care Orchestrator.
Sleep apnea patients have struggled with CPAP therapy during
COVID-19Sleep apnea continues to impact quality of sleep across
the world, with a slight increase reported by those who have been
diagnosed with the issue since last year (2020: 9% vs. 2021: 12%).
While Continuous Positive Airway Pressure (CPAP) therapy is the
most commonly prescribed treatment for the condition, this year’s
survey revealed a drop in the proportion of sleep apnea patients
using their CPAP (2020: 36% vs. 2021: 18%) and an increase in the
proportion who have never used the CPAP they were prescribed (2020:
10% vs. 2021: 16%). With 72% of those who discontinued CPAP
therapy citing COVID-19 related reasons, ranging from financial
challenges (55%) to limited access of supplies (44%), it would
appear that the COVID-19 pandemic has been an inhibiting factor in
CPAP therapy compliance. Perhaps most concerning, however, was that
57% of those living with sleep apnea had never been prescribed CPAP
at all.
Anyone who believes they or a loved one may be at risk for sleep
apnea can visit Philips.com/SleepApnea to take an online symptoms
quiz, and speak to a healthcare professional right away.
Philips’ latest global sleep survey findings further solidify
the company’s commitment to developing clinically-proven solutions
to empower those living with sleep apnea and those facing other
sleep challenges to take control of their health. For more than 35
years, Philips has been studying sleep from every angle, collecting
billions of nights of sleep data to better understand how sleep
affects health. Today, Philips’ growing portfolio of sleep
solutions collectively address more than 80% of known sleep issues
[2]. These solutions and services are supported by clinical
research and technical data to offer scientifically personalized
care and instill confidence among those who use them.
COVID-19 may have forever impacted the healthcare industry,
and sleep care is clearly no exception. Since the beginning of
2020, for example, Philips has seen a 35% increase in the average
number of unique devices connecting to its cloud-based sleep and
respiratory remote patient management software [3], highlighting
the need for such solutions.
To learn more about the Global Sleep Survey and Philips’
commitment to improving access to sleep technology worldwide, visit
Philips.com/WorldSleepDay. To learn more about Philips sleep
solutions, visit Philips.com/SmartSleep. To join the conversation
about sleep health and Philips’ growing suite of consumer and
physician-prescribed sleep solutions, follow @Philips,
@PhilipsSleepWellness or @PhilipsResp.
[1] Indicates net “somewhat” or “complete” agreement with the
statement[2] Snoring, Short Sleep, Insomnia, and Obstructive Sleep
Apnea[3] Based on snapshot data from Philips Encore Anywhere
database. Percent change between Average daily unique devices
connecting to Encore Anywhere by US companies = 1,490,341 as of
12/31/2019 and Average daily unique devices connecting to Encore
Anywhere by US companies = 2,005,352 as of 10/1/2020
For further information, please contact:
Meredith AmorosoPhilips Global Press Office Mobile: +1
724-584-8991E-mail: meredith.amoroso@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2019 sales of EUR 19.5 billion and
employs approximately 81,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
About the SurveyThis survey was conducted online by KJT
Group, Inc. on behalf of Philips from November 17 – December 7,
2020 among 13,000 adults ages 18 and older in 13 countries
(Australia: n=1,000; Brazil: n=1,000; China: n=1,000; France:
n=1,000; Germany: n=1,001; India: n=1,000; Italy: n=1,000; Japan:
n=1,000; Netherlands: n=1,000; Singapore: n=1,000; South Korea:
n=999; United Kingdom: n=1,000; and the U.S.: n=1,000). The survey
was web-based and self-administered in the primary language(s) of
each country. These were non-probability samples and thus a margin
of error cannot be accurately estimated. For complete survey
methodology, including weighting variables, please
contact Meredith Amoroso at meredith.amoroso@philips.com.
- Woman Sleeping
- New Sleep Challenges
- COVID-19 affects sleep apnea patients
- Telehealth for Sleep
- Philips 2021 Global Sleep Survey Results
- Philips 2021 Global Sleep Survey Infographic
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From May 2023 to May 2024